Blog

Becoming a substantial holder - Cyntec

May 14, 2024

Becoming a substantial holder - ZYBT

May 14, 2024

Response to ASX Aware Query

May 1, 2024

Quarterly Cashflow Report and Business Update - period ending 31 March 2024

Apr 30, 2024

Meet Cambium Bio team at BIO International Convention in San Diego

Apr 17, 2024

Notice of change of interests of substantial holder

Apr 11, 2024

Director's Appointment - Dr. Tseng

Apr 11, 2024

Initial DIrector's Interest Notice - Dr. Tseng

Apr 11, 2024

Placement Shares Cleansing Notice

Apr 10, 2024

Application for quotation of securities (10 April 2024)

Apr 10, 2024

Proposed issue of securities

Apr 8, 2024

Change of company name and ASX code

Apr 8, 2024

Ceasing to be a substantial holder - Vesey

Apr 8, 2024

Ceasing to be a substantial holder - Lee

Apr 8, 2024

Ceasing to be a substantial holder - Kirman 2

Apr 8, 2024

Cambium Bio Limited - Corporate Presentation

Apr 6, 2024

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Apr 5, 2024

Resignation of Non-Executive Director - Lee

Apr 5, 2024

Consideration Shares Cleansing Notice

Apr 5, 2024

Notice of initial substantial holder

Apr 5, 2024

Application for quotation of securities

Apr 5, 2024

Final Director's Interest Notice - Lee

Apr 5, 2024

Initial Director's Interest Notice - Walts

Apr 5, 2024

Initial Director's Interest Notice - Waller

Apr 5, 2024

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Feb 6, 2024

Cambium Bio Limited Half Year Report

Dec 31, 2023

Cambium Bio Limited Annual Report

Jun 30, 2023

Process for Evaluating Board and Executive Performance

Apr 8, 2023

Whistleblower Policy

Apr 8, 2023

Securities Trading Policy

Apr 8, 2023

Shareholder Communication Policy

Apr 8, 2023

Continuous Disclosure Policy

Apr 8, 2023

Audit and Risk Committee Charter

Apr 8, 2023

Anti-Bribery and Corruption Policy

Apr 8, 2023

Code of Conduct

Apr 8, 2023

Statement of Values

Apr 8, 2023

Board Skills Matrix

Apr 8, 2023

Remuneration and Nominations Committee Charter

Apr 8, 2023

Diversity Policy

Apr 8, 2023

Board Charter

Apr 8, 2023

Corporate Governance Statement

Apr 8, 2023

Cambium Bio Raises A$3.48 Million in Strategic Placement

Apr 8, 2023

Regeneus Completes Merger with Cambium Medical Technologies LLC

Apr 8, 2023